Olink Explore 384 Cardiometabolic & Cardiometabolic II

The most comprehensive, high-performance protein biomarker panel available for cardiovascular and metabolic studies

The flexibility and scalability of our Olink^® Explore platform can be utilized either for full-scale screening of our entire library of 3072 assays, or in studies that focus on one or several of the eight Explore 384-plex panels that make up the Explore 3072 library.

Key features of Olink Explore 384 biomarker panels

Allows for simultaneous analysis of 384 protein biomarkers
Uses only 1 µL of biological sample
Has similar sensitivity and specificity compared to Olink Target 96-plex and 48-plex products with qPCR readout
Achieves a high level of multiplexing without any compromise on data quality, thanks to our proprietary PEA technology.

About Olink Explore 384 Cardiometabolic and Cardiometabolic II

This panel contains assays related to cardiovascular and metabolic pathways and processes, as well as other proteins that can be considered as more exploratory biomarkers. The majority of the assays in our Olink® Target 96 Cardiovascular II, Cardiovascular III, Metabolic, and Cardiometabolic panels are included in the Explore 384 Cardiovascular panel.

The Explore 384 Cardiometabolic and Cardiometabolic II panels offer simultaneous analysis of 384 of these protein biomarkers using just 1 µL of biological sample. All assays are subject to Olink’s strict technical validation and Quality Control procedures.

Want to learn more?

Search Olink Explore protein biomarker

Assay details

The assays in different Explore 384 panels are divided into different probe pools, called blocks, with different sample dilution factors to ensure optimal read-out quality.

Sample dilution factors

	The Cardiodmetabolic panel ›	1:1	1:10	1:100	1:1000
	The Cardiodmetabolic II panel ›	1:1	1:10	1:100

Note that relevant cardiovascular biomarkers can also be placed in other Explore 384 panels for optimal readout quality.

Our technical validation of assays are performed in vitro using recombinant analytes. All technical validation data reported on the biomarker pages are based on these in vitro assays.